IP-10 as a Biomarker for Tuberculosis Therapy Monitoring
Author Information
Author(s): Kabeer Basirudeen Syed Ahamed, Raja Alamelu, Raman Balambal, Thangaraj Satheesh, Leportier Marc, Ippolito Giuseppe, Girardi Enrico, Lagrange Philippe Henri, Goletti Delia
Primary Institution: Tuberculosis Research Centre (ICMR), Tamil Nadu, Chennai, India
Hypothesis
Can IP-10 response to RD1 peptides serve as a biomarker for monitoring tuberculosis therapy?
Conclusion
IP-10 response to RD1 selected peptides may be a useful biomarker for monitoring therapy efficacy in patients with active tuberculosis.
Supporting Evidence
- IP-10 levels significantly decreased in response to RD1 selected peptides after treatment.
- 94.1% of subjects were positive for IP-10 at the time of TB diagnosis.
- 82.3% of subjects were positive for IP-10 at therapy completion.
- IFN-γ response showed similar trends to IP-10 in monitoring treatment efficacy.
Takeaway
This study looked at a protein called IP-10 to see if it can help doctors know how well tuberculosis treatment is working. They found that IP-10 levels changed in patients after treatment.
Methodology
The study assessed changes in IP-10 secretion in response to QFT-IT antigens and RD1 peptides in 17 patients with active TB before and after 6 months of treatment.
Potential Biases
Potential bias due to the small sample size and unknown BCG vaccination status.
Limitations
The study was conducted on a small number of subjects (17) and the BCG status of the patients was unknown.
Participant Demographics
Median age of participants was 32 years, with 52.9% being male.
Statistical Information
P-Value
p = 0.006
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website